Skip to main content
SpringerLink
Log in

QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

QVA149 (indacaterol/glycopyrronium) [Xoterna® Breezhaler®, Ultibro® Breezhaler®] is an inhaled fixed-dose combination of indacaterol (a long-acting selective β2-adrenergic receptor agonist [LABA]) and glycopyrronium (a long-acting muscarinic receptor antagonist [LAMA]) that has been approved in the EU and Japan for the symptomatic control of chronic obstructive pulmonary disease (COPD) in adults. In phase III studies, QVA149 significantly improved bronchodilation versus indacaterol, glycopyrronium or tiotropium alone and the LABA/inhaled corticosteroid fixed-dose combination salmeterol/fluticasone. These improvements in lung function, which were rapid in onset and maintained during long-term treatment, were generally associated with significant improvements in dyspnoea, health status, COPD exacerbation risk, patient symptoms, and rescue medication use. The SHINE and ILLUMINATE studies in low (exacerbation) risk patients with moderate to severe disease suggest that QVA149 may offer more symptomatic relief than tiotropium and salmeterol/fluticasone. Similarly, the SPARK study in high (exacerbation) risk patients with severe or very severe disease showed that QVA149 was more effective than glycopyrronium in preventing moderate to severe exacerbations, and suggests that QVA149 may offer more symptomatic relief than LAMA monotherapy. Another phase III study comparing QVA149 with salmeterol/fluticasone in high-risk patients with moderate to very severe disease (FLAME) is ongoing. QVA149 is generally well tolerated, with no new safety signals identified compared with its monocomponents. Bronchodilators remain central to the symptomatic management of COPD. When dual bronchodilation is indicated, QVA149 offers the convenience of two bronchodilators in a single inhaler coupled with a simple, once-daily dosing regimen that may encourage better treatment adherence. Therefore, it is a valuable option in the treatment of COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72(4):543–63.

    Article  CAS  PubMed  Google Scholar 

  2. Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741–53.

    Article  CAS  PubMed  Google Scholar 

  3. Novartis. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan [media release]. 23 Sep 2013. http://www.novartis.com/newsroom/media-releases/en/2013/1730580.shtml.

  4. Novartis Pharma K.K. Ultibro inhalation capsules: Japanese prescribing information. 2013. http://product.novartis.co.jp/ult/pi/ULT1309_03.pdf. Accessed 31 Jan 2014.

  5. Novartis Europharm Ltd. Ultibro Breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002679/WC500151255.pdf. Accessed 13 Nov 2013.

  6. Dahl R, Dalal J, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J COPD. 2013;8:501–8.

    Article  CAS  Google Scholar 

  7. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–62.

    Article  CAS  PubMed  Google Scholar 

  8. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–9.

    Article  PubMed  Google Scholar 

  9. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med. 2010. doi:10.1186/1471-2466-10-11.

    PubMed Central  PubMed  Google Scholar 

  10. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273–9.

    Article  CAS  PubMed  Google Scholar 

  11. Korn S, Kerwin E, Atis S, et al. Indacaterol once daily provides superior efficacy to salmeterol twice daily in COPD: a 12-week study. Respir Med. 2011;105(5):719–26.

    Article  PubMed  Google Scholar 

  12. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797–803.

    Article  CAS  PubMed  Google Scholar 

  13. DeCramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–33.

    Google Scholar 

  14. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68–75.

    Article  CAS  PubMed  Google Scholar 

  15. Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther. 2011;49(2):153–61.

    Article  CAS  PubMed  Google Scholar 

  16. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520–8.

    Article  CAS  PubMed  Google Scholar 

  17. D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011. doi:10.1186/1465-9921-12-156.

    PubMed Central  PubMed  Google Scholar 

  18. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Drollmann A, Brown M, Sechaud R, et al. Effect of once-daily QVA149 on cardiac safety in healthy volunteers [abstract no. F64]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).

  20. Van de Maele B, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237. COPD patients. COPD. 2010;7(6):418–27.

    Article  PubMed  Google Scholar 

  21. Cazzola M, Calzetta L, Page CP, et al. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014;10(1):129–37.

    Article  CAS  PubMed  Google Scholar 

  22. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Ultibro Breezhaler. International non-proprietary names: indacaterol /glycopyrronium bromide. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002679/WC500151257.pdf. Accessed 14 Nov 2013.

  23. Asai K, Minakata Y, Hirata K, et al. Once-daily QVA149 is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  24. Novartis Pharmaceuticals. Long term safety and tolerability of QVA149 versus tiotropium in Japanese patients with chronic obstructive pulmonary disease (COPD) (ARISE) [ClinicalTrials.gov identifier NCT01285492]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/show/NCT01285492. Accessed 9 Oct 2013.

  25. Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. 2013. doi:10.1183/09031936.00124013.

  26. Mahler DA, Decramer M, D’Urzo AD, et al. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium In COPD patients: the BLAZE study [abstract P236 plus oral presentation]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).

  27. Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014. doi:10.1016/j.rmed.2014.01.006.

    PubMed  Google Scholar 

  28. Novartis Pharmaceuticals. Effect of QVA149 on exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) (BRIGHT) [ClinicalTrials.gov identifier NCT01294787]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/show/NCT01294787. Accessed 9 Oct 2013.

  29. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558–67.

    Article  PubMed  Google Scholar 

  30. Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnoea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  31. Novartis Pharmaceuticals. A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate/glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD (FLAME) [ClinicalTrials.gov identifier NCT01782326]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/show/NCT01782326. Accessed 9 Oct 2013.

  32. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.

    Article  CAS  PubMed  Google Scholar 

  33. Bateman ED, Vogelmeier C, Pallante J, et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study [abstract no. 807]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).

  34. Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  35. Vogelmeier C, Dahl R, D’Urzo A, et al. Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  36. Barnes N, Hashimoto S, Nagase T, et al. QVA149 provides superior peak lung function in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  37. Gallagher N, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  38. Welte T, Dahl R, Chen H, et al. Once-daily QVA149 improves symptom scores in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  39. Novartis Pharmaceuticals. A 26-week treatment randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 (indacaterol/glycopyrronium bromide) compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary disease [ClinicalTrials.gov identifier NCT01709903]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/show/NCT01709903. Accessed 9 Oct 2013.

  40. Novartis Pharmaceuticals. Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation (RADIATE) [ClinicalTrials.gov identifier NCT01610037]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/show/NCT01610037. Accessed 9 Oct 2013.

  41. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–94.

    Google Scholar 

  42. Welte T, Gallagher N, Green Y, et al. Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract no. G25]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).

  43. Bateman ED, Ferguson GT, Welte T, et al. Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol/fluticasone [abstract no. G30]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).

  44. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.

    Article  CAS  PubMed  Google Scholar 

  45. Ficker J, Wedzicha JA, Decramer M, et al. QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: the SPARK study [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  46. Banerji D, Fowler Taylor A, Kho P, et al. Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: a 52 week pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  47. Wedzicha JA, Decramer M, Vestbo J, et al. A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  48. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111–24.

    Article  PubMed  Google Scholar 

  49. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–69.

    Article  CAS  PubMed  Google Scholar 

  50. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–5.

    Article  PubMed  Google Scholar 

  51. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103.

    Article  PubMed  Google Scholar 

  52. Jones PW. St George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–9.

    Article  PubMed  Google Scholar 

  53. Welte T, Vogelmeier C, Dahl R, et al. Once-daily QVA149 has a good safety profile in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  54. Ferguson GT, Barnes N, Mehta R, et al. Cardio- and cerebro-vascular safety of QVA149: results from a pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  55. Chen H, D’Andrea P, Banerji D. QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: a network meta-analysis across multiple safety databases [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.

  56. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2014). http://www.goldcopd.org/. Accessed 30 Jan 2014.

  57. Gladysheva ES, Malhotra A, Owens RL. Influencing the decline of lung function in COPD: use of pharmacotherapy. Int J COPD. 2010;5:153–64.

    CAS  Google Scholar 

  58. Lemmens V, Oenema A, Knut IK, et al. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev. 2008;17(6):535–44.

    Article  PubMed  Google Scholar 

  59. Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7:17–34.

    PubMed Central  PubMed  Google Scholar 

  60. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–91.

    Article  PubMed  Google Scholar 

  61. National Institute for Health and Clinical Excellence. CG101 Chronic obstructive pulmonary disease (updated): NICE guideline. http://guidance.nice.org.uk/CG101/NICEGuidance/pdf/English. Accessed 5 Dec 2013.

  62. Spina D. Current and novel bronchodilators in respiratory disease. Curr Opin Pulm Med. 2014;20(1):73–86.

    Article  CAS  PubMed  Google Scholar 

  63. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14(1):49.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2006;1(4):409–23.

    CAS  PubMed Central  PubMed  Google Scholar 

  65. Boehringer Ingelheim. New once-daily Striverdi® (olodaterol) Respimat® gains approval in first EU countries [media release]. 18 Oct 2013. https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/18_october_2013_olodaterol.html.

  66. GlaxoSmithKline plc, and Theravance Inc. RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD [media release]. 18 Nov 2013. http://www.gsk.com/media/press-releases/2013/relvar-ellipta-receives-european-marketing-authorisation-for-t.html.

  67. Jacobsen JR, Choi SK, Combs J, et al. A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2012;22(2):1213–8.

    Article  CAS  PubMed  Google Scholar 

  68. Bateman ED, Make BJ, Nandeuil MA. Safety and tolerability of a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008;177:A653.

    Google Scholar 

  69. Aparici M, Gómez-Angelats M, Vilella D, et al. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favourable safety profile in preclinical models. J Pharmacol Exp Ther. 2012;342(2):497–509.

    Article  CAS  PubMed  Google Scholar 

  70. Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477–95.

    Article  CAS  PubMed  Google Scholar 

  71. Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother. 2013;47(7–8):1017–28.

    Article  PubMed  Google Scholar 

  72. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247–68.

    Article  CAS  PubMed  Google Scholar 

  73. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260–70.

    Article  CAS  PubMed  Google Scholar 

  74. GlaxoSmithKline plc. GSK announces regulatory submission for umeclidinium monotherapy in European Union [media release]. 26 Apr 2013. http://www.gsk.com/media/press-releases/2013/GSK-announces-egulatory-ubmission-or-meclidinium-onotherapy-in-european-union.html.

  75. GlaxoSmithKline plc, and Theravance Inc. GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe [media release]. 8 Jan 2013. http://www.gsk.com/media/press-releases/2013/gsk-and-theravance-announce-regulatory-submission-for-anoro-umec-vi-in-europe.html.

  76. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013. doi:10.1186/1465-9921-14-49.

    PubMed Central  PubMed  Google Scholar 

  77. Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26(1):145–55.

    Article  CAS  PubMed  Google Scholar 

  78. Pera T, Zuidhof A, Valadas J, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J. 2011;38:789–96.

    Article  CAS  PubMed  Google Scholar 

  79. Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–96.

    Google Scholar 

  80. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–41.

    Article  PubMed  Google Scholar 

  81. Roche N, Chanez P. Bronchodilator combinations for COPD: real hopes or a new Pandora’s box? Eur Respir J. 2013;42:1441–5.

    Article  CAS  PubMed  Google Scholar 

  82. Schachter EN. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc). 2013;49(7):437–46.

    CAS  Google Scholar 

  83. UK Medicines Information. New drugs online report for formoterol + glycopyrrolate. http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5371. Accessed 4 Dec 2013.

  84. Almirall, S.A. Aclidinium and formoterol fixed dose combination for COPD submitted for registration in Europe [media release]. 4 November 2013. http://investors.almirall.es/phoenix.zhtml?c=209345&p=irol-newsArticle&ID=1871606&highlight=.

  85. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26(3):307–17.

    Article  CAS  PubMed  Google Scholar 

  86. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir Med. 2013;1(3):210–23.

    Article  CAS  PubMed  Google Scholar 

  87. Cyr M-C, Beauchesne M-F, Lemière C, et al. Effects of inhaled corticosteroids in monotherapy or combined with long-acting β2-agonists on mortality among patients with chronic obstructive pulmonary disease. Ann Pharmacother. 2010;44(4):613–22.

    Article  CAS  PubMed  Google Scholar 

  88. GlaxoSmithKline. Seretide Diskus 50/100 microgram/dose inhalation powder, predispensed: EU summary of product characteristics. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Seretide_Diskus_6_13/WC500013534.pdf. Accessed 5 Dec 2013.

  89. Astra Zeneca UK Ltd. Symbicort® Turbohaler® 100 micrograms/6 micrograms/inhalation, inhalation powder: summary of product characteristics. 2013. http://www.medicines.org.uk/emc/medicine/4820. Accessed 5 Dec 2013.

  90. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J COPD. 2012;7:73–86.

    CAS  Google Scholar 

  91. Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477–95.

    Article  CAS  PubMed  Google Scholar 

  92. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991.

    Google Scholar 

  93. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.

    Google Scholar 

  94. Anton E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med. 2013;7(Suppl 2):25–32.

    Article  CAS  PubMed  Google Scholar 

  95. Thomas M, Radwan A, Stonham C, et al. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2013. doi:10.3109/15412555.2013.841671.

    Google Scholar 

  96. Novartis. Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149) [media release]. 8 Sep 2013. http://www.novartis.com/newsroom/media-releases/en/2013/1727858.shtml.

  97. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008;133(5):1079–87.

    Article  CAS  PubMed  Google Scholar 

  98. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. New Engl J Med. 2013;369:1491–501.

    Article  CAS  PubMed  Google Scholar 

  99. Rutten-van Mölken MP. Goossens M. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30(4):271–302.

    Article  PubMed  Google Scholar 

  100. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax. 2008;63:962–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Additional information

The manuscript was reviewed by: R. Buhl, Pulmonary Department, Mainz University Hospital, Mainz, Germany; M. Cazzola, Unit of Respiratory Clinical Pharmacology, Department of System Medicine, University of Rome “Tor Vergata”, Rome, Italy; R. Dahl, Allergy Centre, Odense University Hospital, Odense, Denmark; A.D. D’Urzo, Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; P.P. Montuschi, Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy; L.J. Nannini, Hospital de G Baigorria, Universidad Nacional Rosario, Rosario, Argentina; D.D. Spina, Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Biomedical and Health Sciences, King’s College London, London, England; A.M. Turner, QEHB Research Labs, University of Birmingham, Birmingham, England.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease. Drugs 74, 465–488 (2014). https://doi.org/10.1007/s40265-014-0194-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0194-8

Keywords

Search

Navigation